The clinical trial details are clearly outlined, yet the specific eligibility criteria and associated costs for participants remain unspecified in the provided documentation.
Questions about Dan Fehring
What is Dan Fehring?
Dan Fehring leads a translational research program based in Melbourne, Australia, focused on developing brain circuit therapeutics for addiction and related disorders. The program combines personalised neurostimulation, neuroimaging, and rapid clinical trials to map individual circuit signatures and match interventions to disrupted brain circuits.
How does the program translate research into clinical impact?
The program translates findings by testing rapid interventions against clinical, cognitive, and biological outcomes. This process moves from cellular mechanisms to clinical application to achieve measurable real-world change.
What international partnerships support the research program?
The research connects foundational work with international partners at RIKEN Center for Brain Science to clinical translation at Monash University. It aims to move from broad, one-size-fits-all stimulation towards interventions matched to the person and the circuit.
Who is the program designed for?
The program is designed for individuals with addiction and related disorders where the same diagnosis can reflect different patterns of disrupted control, reward, and interoception. It turns that variability into a treatment strategy.
What is the alcohol use disorder trial about?
The program includes a double-blind, sham-controlled umbrella trial testing whether connectivity-defined biotypes can guide stimulation of lateral or medial prefrontal circuits for alcohol use disorder. It involves 160 participants with a rapid 5-day intervention and a 90-day follow-up.
How does the TailorED study adapt treatment?
The TailorED study adapts treatment to early response for bulimia nervosa and binge eating disorder. For non-rapid responders, one pathway combines motivational interviewing, cognitive training, and learning-enhanced TMS.
What is the Path-OUD study investigating?
The Path-OUD study is a controlled study testing whether psilocybin-assisted therapy can reduce non-prescribed opioid use, improve treatment adherence, and alter brain function for opioid use disorder.
What is the SMART trial design?
The program uses a multi-centre SMART trial design to ask practical questions about who should receive which intervention, at which target, and in which direction. Each study asks a practical question regarding intervention selection.
Where is the program located?
The program is located in Melbourne, Australia, and operates through the Turner Institute for Brain and Mental Health and the Monash Addiction Research Centre. It is based at Monash University.
What technologies are used in the program?
The program uses technologies such as deep transcranial magnetic stimulation, focused ultrasound, and transcranial direct current stimulation alongside functional MRI, spectroscopy, and computational modelling.
What is the primary goal of the program?
The program aims to understand, target, and recalibrate the circuits disrupted in addiction and related disorders. It focuses on personalised brain stimulation and neuroimaging to achieve this goal.
What is the official website of Dan Fehring?
The official website of Dan Fehring is danfehring.com.
How is Dan Fehring rated on Trustburn?
On Trustburn, Dan Fehring has a rating of 3.8 out of 5 based on 5 reviews.
Post your question publicly — other visitors, and whoever manages this page, can answer. It will be visible on this page.
Want to hear about this company again? Follow it and we’ll email you when a new review appears.
Based on reviews, listing data and the company's website. Verify anything important with the company directly.
Dan Fehring’s research program at the Turner Institute for Brain and Mental Health presents a compelling model of translational neuroscience. By combining causal neuroscience, advanced imaging, and rapid clinical trials, the initiative moves beyond one-size-fits-all stimulation towards personalized interventions. The three-step logic of mapping circuit signatures, matching targeted interventions like deep TMS or focused ultrasound, and translating findings into measurable clinical changes is particularly noteworthy. The portfolio includes a Phase 2 umbrella trial for alcohol use disorder and the TailorED study for bulimia and binge eating disorder, indicating a strong focus on addiction and related disorders. Collaboration with the RIKEN Center for Brain Science further enhances the program's scientific rigor. The selection of publications highlights mechanistic evidence and trial protocols, suggesting a commitment to rigorous scientific standards. This infrastructure connects foundational work with international partners, creating reusable assets for new collaborations while maintaining a clear anchor to specific clinical needs. The approach seems well-positioned to advance precise brain interventions for complex neurological conditions.
The clinical trial portfolio showcases a clear progression from discovery to clinical impact, utilizing rapid interventions and biomarkers. The umbrella trial for alcohol use disorder and the TailorED study for eating disorders demonstrate adaptive designs that seem efficient. While the scientific infrastructure appears robust and well-integrated with Monash University, the specific financial implications of these targeted interventions remain unclear from the current information. It is notable that the program emphasizes measurable change across biological and clinical outcomes. For researchers considering collaboration, the shared approach connecting clinical phenotyping to targeted intervention offers a scalable model. The question remains whether these precise, evidence-led interventions are accessible to broader patient populations beyond the specific trials mentioned. The structured transition from cellular mechanisms to clinical application suggests a promising pathway for future therapeutic developments.
The integration of functional MRI with deep TMS and focused ultrasound represents a sophisticated methodological framework. This personalized strategy for mapping circuit signatures appears highly effective for targeting disrupted control and reward pathways in addiction disorders.
Dan Fehring leads a translational research program focusing on precision brain circuit therapeutics for addiction and related disorders.
Questions & Answers
No questions yet — be the first to ask.
Sign in to post
Your text is saved — you'll come right back to post.
Don't have an account? Create one
News & Press
No news yet. This is where the business shares its own updates and press.
Photos
No photos yet. Photos shared by reviewers will show up here.
About Dan Fehring
Dan Fehring leads a translational research program based in Melbourne, Australia, focused on developing brain circuit therapeutics for addiction and related disorders. The program combines personalised neurostimulation, neuroimaging, and rapid clinical trials to map individual circuit signatures, match interventions to disrupted brain circuits, and measure clinical and biological outcomes. Technologies used or investigated include deep transcranial magnetic stimulation, focused ultrasound, and transcranial direct current stimulation, alongside functional MRI, spectroscopy, and computational modelling. The work connects foundational neuroscience conducted with international partners such as RIKEN Center for Brain Science with clinical translation at Monash's Turner Institute for Brain and Mental Health and the Monash Addiction Research Centre.
- Website
- danfehring.com
- [email protected]
